Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors.
Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Müller-Holzner E, Jones A, Widschwendter M. Berger R, et al. Among authors: egle d. Cancer Sci. 2010 Apr;101(4):1059-66. doi: 10.1111/j.1349-7006.2010.01491.x. Epub 2010 Jan 12. Cancer Sci. 2010. PMID: 20156214 Free PMC article.
Epigenetic stem cell signature in cancer.
Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Widschwendter M, et al. Among authors: egle d. Nat Genet. 2007 Feb;39(2):157-8. doi: 10.1038/ng1941. Epub 2006 Dec 31. Nat Genet. 2007. PMID: 17200673
HE4 is an independent prognostic marker in endometrial cancer patients.
Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A. Mutz-Dehbalaie I, et al. Among authors: egle d. Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21. Gynecol Oncol. 2012. PMID: 22525819
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Singer CF, et al. Among authors: egle d. Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31. Clin Cancer Res. 2017. PMID: 28143867 Clinical Trial.
Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality.
da Silva I, da Costa Vieira R, Stella C, Loturco E, Carvalho AL, Veo C, Neto C, Silva SM, D'Amora P, Salzgeber M, Matos D, Silva CR, Oliveira JR, Rabelo I, Yamakawa P, Maciel R, Biscolla R, Chiamolera M, Fraietta R, Reis F, Mori M, Marchioni D, Carioca A, Maciel G, Tomioka R, Baracat E, Silva C, Granato C, Diaz R, Scarpellini B, Egle D, Fiegl H, Himmel I, Troi C, Nagourney R. da Silva I, et al. Among authors: egle d, d amora p. Oncotarget. 2018 Aug 3;9(60):31664-31681. doi: 10.18632/oncotarget.25839. eCollection 2018 Aug 3. Oncotarget. 2018. PMID: 30167086 Free PMC article.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. Mayer IA, et al. Among authors: egle d. Clin Cancer Res. 2019 May 15;25(10):2975-2987. doi: 10.1158/1078-0432.CCR-18-3160. Epub 2019 Feb 5. Clin Cancer Res. 2019. PMID: 30723140 Free PMC article. Clinical Trial.
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Singer CF, Pfeiler G, Hubalek M, Bartsch R, Stöger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Maria Tea MK, Wette V, Petzer AL, Sevelda P, Egle D, Dubsky PC, Filipits M, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Frantal S, Gnant M; Austrian Breast & Colorectal Cancer Study Group. Singer CF, et al. Among authors: egle d. Eur J Cancer. 2020 Jun;132:43-52. doi: 10.1016/j.ejca.2020.03.018. Epub 2020 Apr 20. Eur J Cancer. 2020. PMID: 32325419 Clinical Trial.
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC, Singer CF, Egle D, Wette V, Petru E, Balic M, Pichler A, Greil R, Petzer AL, Bago-Horvath Z, Fesl C, Meek SM, Kronenwett R, Rudas M, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group. Dubsky PC, et al. Among authors: egle d. Eur J Cancer. 2020 Jul;134:99-106. doi: 10.1016/j.ejca.2020.04.020. Epub 2020 Jun 2. Eur J Cancer. 2020. PMID: 32502940 Free article. Clinical Trial.
80 results